Obesity and the Endocannabinoid System: Is There Still a Future for CB1 Antagonists in Obesity?

Current Obesity Reports

Volumn 1, Issue 4, 2012, Pages 216-228

  Serrano, Antonia ^a   Pavon, Francisco Javier ^a   Suarez, Juan ^a   Romero Cuevas, Miguel ^a   Baixeras, Elena ^a   Goya, Pilar ^b   de Fonseca, Fernando Rodríguez ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b INSTITUTO DE QUÍMICA MÉDICA   (Spain)

Author keywords

Anandamide; Appetite; Cannabinoid receptors; Diabetes; Endocannabinoids; Obesity; Therapy

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; AM6545; ANANDAMIDE; ANTIOBESITY AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; CHOLECYSTOKININ; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; CORTICOTROPIN RELEASING FACTOR; ENDOCANNABINOID; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FATTY ACID AMIDASE; GHRELIN; GLUCAGON; INSULIN; JD 5006; LEPTIN; LH 21; MORPHINE; N OLEOYLETHANOLAMINE; NALOXONE; OREXIN; OREXIN 1 RECEPTOR; OREXIN A; RIMONABANT; SIBUTRAMINE; SNAP 94847; SURINABANT; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; URB447;

ADIPOSE TISSUE; ANXIETY; APPETITE; CLINICAL TRIAL (TOPIC); DIZZINESS; FOOD INTAKE; GASTROINTESTINAL TRACT; HUMAN; LIVER; MITOCHONDRION; NAUSEA; NONHUMAN; OBESITY; PANCREAS ISLET; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84875230354     PISSN: None     EISSN: 21624968     Source Type: Journal    
DOI: 10.1007/s13679-012-0031-x     Document Type: Review

References (138)

1. • Pertwee RG, Howlett AC, Abood ME, et al. International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev. 2010;62(4): 588-631. The most recent consensus on the identification, description, nomenclature and properties of cannabinoid receptors and their endogenous ligands.
2. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258(5090): 1946-9.
3. Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 1995;50(1): 83-90.
4. Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun. 1995;215(1): 89-97.
5. Batkai S, Jarai Z, Wagner JA, et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med. 2001;7(7): 827-32.
6. Herkenham M, Lynn AB, Johnson MR, et al. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci. 1991;11(2): 563-83.
7. Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A. 1990;87(5): 1932-6.
8. Howlett AC, Bidaut-Russell M, Devane WA, et al. The cannabinoid receptor: biochemical, anatomical and behavioral characterization. Trends Neurosci. 1990;13(10): 420-3.
9. Onaivi ES, Ishiguro H, Gong JP, et al. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci. 2006;1074: 514-36.
10. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365(6441): 61-5.
11. • Godlewski G, Offertaler L, Wagner JA, et al. Receptors for acylethanolamides-GPR55 and GPR119. Prostaglandins Other Lipid Mediat. 2009;89(3-4): 105-11. Two new orphan receptors as targets of endogenous lipid transmitters related to the endogenous cannabinoid system. While Lysophosphatidyl inositol activates GPR55, oeloylethanolamide is proposed to be the endogenous ligand of GPR119. Both are relevant targets in obesity and type 2 diabetes.
12. Okamoto Y, Morishita J, Tsuboi K, et al. Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem. 2004;279(7): 5298-305.
13. Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature. 1997;388(6644): 773-8.
14. Cravatt BF, Giang DK, Mayfield SP, et al. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 1996;384(6604): 83-7.
15. Dinh TP, Carpenter D, Leslie FM, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A. 2002;99(16): 10819-24.
16. Ueda N, Tsuboi K, Uyama T. Enzymological studies on the biosynthesis of N-acylethanolamines. Biochim Biophys Acta. 2010;1801(12): 1274-85.
17. Marquez L, Suarez J, Iglesias M, et al. Ulcerative colitis induces changes on the expression of the endocannabinoid system in the human colonic tissue. PLoS One. 2009;4(9): e6893.
18. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest. 2005;115(5): 1298-305.
19. • Crespillo A, Suarez J, Bermudez-Silva FJ, et al. Expression of the cannabinoid system in muscle: effects of a high-fat diet and CB1 receptor blockade. Biochem J. 2011;433(1): 175-85. The endogenous cannabinoid system is in the muscle. This paper describes its presence and the impact of caloric diets on its expression and fucntion.
20. Bermudez-Silva FJ, Suarez J, Baixeras E, et al. Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia. 2008;51(3): 476-87.
21. Cota D, Marsicano G, Tschop M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest. 2003;112(3): 423-31.
22. Pagotto U, Marsicano G, Cota D, et al. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev. 2006;27(1): 73-100.
23. • Quarta C, Mazza R, Obici S, et al. Energy balance regulation by endocannabinoids at central and peripheral levels. Trends Mol Med. 2011;17(9): 518-26. This review addresses the general role of the ECS in the regulation of energu expenditure, and discuss the contribution of central (CNS) and peripheral (adipose tissue, liver, pancreas) organs.
24. Engeli S. Dysregulation of the endocannabinoid system in obesity. J Neuroendocrinol. 2008;20 Suppl 1: 110-5.
25. Di Marzo V. CB1 receptor antagonism: biological basis for emtabolic effects. Drug Discovery Today. 2008;13(23/24): 1026-41.
26. South T, Huang XF. Temporal and site-specific brain alterations in CB1 receptor binding in high fat diet-induced obesity in C57Bl/6 mice. J Neuroendocrinol. 2008;20(11): 1288-94.
27. • Massa F, Mancini G, Schmidt H, et al. Alterations in the hippocampal endocannabinoid system in diet-induced obese mice. J Neurosci. 2010;30(18): 6273-81. This paper describes how high fat diet affects the endogenous cannabinoid system in the hippocampus. It clearly establish that nutritional aspects might regulate this system, so a net behavioural contribution can be expects as results of obesity-induced ECS alterations.
28. Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature. 2001;410(6830): 822-5.
29. Bluher M, Engeli S, Kloting N, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes. 2006;55(11): 3053-60.
30. Matias I, Gonthier MP, Orlando P, et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab. 2006;91(8): 3171-80.
31. Monteleone P, Matias I, Martiadis V, et al. Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology. 2005;30(6): 1216-21.
32. • Fanelli F, Di Lallo VD, Belluomo I, et al. Estimation of reference intervals of five endocannabinoids and endocannabinoid related compounds in human plasma by two dimensional-LC/MS/MS. J Lipid Res. 2012;53(3): 481-93. First general study on the fluctuations of plasma endocannabinoids in general population that also addresses the impact of obesity. This study also analyze the net effect of different biochemical procedures for estimating plasma concentrations of endocannabinoids.
33. Engeli S, Bohnke J, Feldpausch M, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes. 2005;54(10): 2838-43.
34. Sipe JC, Waalen J, Gerber A, et al. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int J Obes (Lond). 2005;29(7): 755-9.
35. Murdolo G, Kempf K, Hammarstedt A, et al. Insulin differentially modulates the peripheral endocannabinoid system in human subcutaneous abdominal adipose tissue from lean and obese individuals. J Endocrinol Invest. 2007;30(8): RC17-21.
36. Matias I, Petrosino S, Racioppi A, et al. Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: effect of high fat diets. Mol Cell Endocrinol. 2008;286(1-2 Suppl 1): S66-78.
37. Starowicz KM, Cristino L, Matias I, et al. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity (Silver Spring). 2008;16(3): 553-65.
38. Bensaid M, Gary-Bobo M, Esclangon A, et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol. 2003;63(4): 908-14.
39. Liu YL, Connoley IP, Wilson CA, et al. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes (Lond). 2005;29(2): 183-7.
40. Pagano C, Pilon C, Calcagno A, et al. The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. J Clin Endocrinol Metab. 2007;92(12): 4810-9.
41. Kempf K, Hector J, Strate T, et al. Immune-mediated activation of the endocannabinoid system in visceral adipose tissue in obesity. Horm Metab Res. 2007;39(8): 596-600.
42. Thanos PK, Ramalhete RC, Michaelides M, et al. Leptin receptor deficiency is associated with upregulation of cannabinoid 1 receptors in limbic brain regions. Synapse. 2008;62(9): 637-42.
43. Ravinet Trillou C, Arnone M, Delgorge C, et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol. 2003;284(2): R345-53.
44. Vickers SP, Webster LJ, Wyatt A, et al. Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (Berl). 2003;167(1): 103-11.
45. • Judge MK, Zhang Y, Scarpace PJ. Responses to the cannabinoid receptor-1 antagonist, AM251, are more robust with age and with high-fat feeding. J Endocrinol. 2009;203(2): 281-90. This paper addresses the obese-phenotype dependency of the pharmacological response to cannabinoid receptor antagonists.
46. • Kunos G, Tam J. The case for peripheral CB receptor blockade in the treatment of visceral obesity and its cardiometabolic complications. Br J Pharmacol. 2011;163(7): 1423-31. Analysis of the potential role of peripheral cannabinoid receptors in obesity and the impact of therapies aiming at this peripheral target.
47. Williams CM, Rogers PJ, Kirkham TC. Hyperphagia in pre-fed rats following oral delta9-THC. Physiol Behav. 1998;65(2): 343-6.
48. Williams CM, Kirkham TC. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berl). 1999;143(3): 315-7.
49. Ravinet Trillou C, Delgorge C, Menet C, et al. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord. 2004;28(4): 640-8.
50. Thornton-Jones ZD, Kennett GA, Benwell KR, et al. The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake. Pharmacol Biochem Behav. 2006;84(2): 353-9.
51. Riedel G, Fadda P, McKillop-Smith S, et al. Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. Br J Pharmacol. 2009;156(7): 1154-66.
52. Rinaldi-Carmona M, Barth F, Heaulme M, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 1994;350(2-3): 240-4.
53. Fong TM, Guan XM, Marsh DJ, et al. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S, 2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5- (t rifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents. J Pharmacol Exp Ther. 2007;321(3): 1013-22.
54. Nogueiras R, Veyrat-Durebex C, Suchanek PM, et al. Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. Diabetes. 2008;57(11): 2977-91.
55. Tsou K, Brown S, Sanudo-Pena MC, et al. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 1998;83(2): 393-411.
56. Breivogel CS, Sim LJ, Childers SR. Regional differences in cannabinoid receptor/G-protein coupling in rat brain. J Pharmacol Exp Ther. 1997;282(3): 1632-42.
57. Gomez R, Navarro M, Ferrer B, et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci. 2002;22(21): 9612-7.
58. • Quarta C, Bellocchio L, Mancini G, et al. CB(1) signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance. Cell Metab. 2010;11(4): 273-85. This important study clearly establish the role of cannabinoid CB1 receptor located in autonomic adrenergic neurons on the control of weight gain and energy expenditure.
59. • Bellocchio L, Lafenetre P, Cannich A, et al. Bimodal control of stimulated food intake by the endocannabinoid system. Nat Neurosci. 2010;13(3): 281-3. Identification of the opposite role of CB1 receptors located in either GABA or GLUTAMATE neurons on feeding. It sets the molecular basis for the biphasic effects of cannabinoids on feeding behaviour and other motivated behaviours.
60. Hilairet S, Bouaboula M, Carriere D, et al. Hypersensitization of the Orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716. J Biol Chem. 2003;278(26): 23731-7.
61. Wren AM, Small CJ, Abbott CR, et al. Ghrelin causes hyperphagia and obesity in rats. Diabetes. 2001;50(11): 2540-7.
62. Tucci SA, Rogers EK, Korbonits M, et al. The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin. Br J Pharmacol. 2004;143(5): 520-3.
63. Kola B, Farkas I, Christ-Crain M, et al. The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. PLoS One. 2008;3(3): e1797.
64. Lazzari P, Sanna A, Mastinu A, et al. Weight loss induced by rimonabant is associated with an altered leptin expression and hypothalamic leptin signaling in diet-induced obese mice. Behav Brain Res. 2011;217(2): 432-8.
65. Koch JE. Delta(9)-THC stimulates food intake in Lewis rats: effects on chow, high-fat and sweet high-fat diets. Pharmacol Biochem Behav. 2001;68(3): 539-43.
66. Koch JE, Matthews SM. Delta9-tetrahydrocannabinol stimulates palatable food intake in Lewis rats: effects of peripheral and central administration. Nutr Neurosci. 2001;4(3): 179-87.
67. Cooper SJ. Endocannabinoids and food consumption: comparisons with benzodiazepine and opioid palatability-dependent appetite. Eur J Pharmacol. 2004;500(1-3): 37-49.
68. Gardner EL. Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol Biochem Behav. 2005;81(2): 263-84.
69. Cota D, Tschop MH, Horvath TL, et al. Cannabinoids, opioids and eating behavior: the molecular face of hedonism? Brain Res Rev. 2006;51(1): 85-107.
70. McLaughlin PJ, Winston K, Swezey L, et al. The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats. Behav Pharmacol. 2003;14(8): 583-8.
71. Verty AN, McGregor IS, Mallet PE. Consumption of high carbohydrate, high fat, and normal chow is equally suppressed by a cannabinoid receptor antagonist in non-deprived rats. Neurosci Lett. 2004;354(3): 217-20.
72. Hungund BL, Szakall I, Adam A, et al. Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens. J Neurochem. 2003;84(4): 698-704.
73. Naassila M, Pierrefiche O, Ledent C, et al. Decreased alcohol self-administration and increased alcohol sensitivity and withdrawal in CB1 receptor knockout mice. Neuropharmacology. 2004;46(2): 243-53.
74. • Orio L, Crespo I, Lopez-Moreno JA, et al. Additive effects of cannabinoid CB1 receptors blockade and cholecystokinin on feeding inhibition. Pharmacol Biochem Behav. 2011;98(2): 220-6. This study show how the ECS opposes to the anorectic actions of CCK in peripheral nerve terminals. It demonstrates that CCK and a CB1 receptor antagonist can be additive in reducing feeding.
75. Artmann A, Petersen G, Hellgren LI, et al. Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochim Biophys Acta. 2008;1781(4): 200-12.
76. • DiPatrizio NV, Astarita G, Schwartz G, et al. Endocannabinoid signal in the gut controls dietary fat intake. Proc Natl Acad Sci U S A. 2011;108(31): 12904-8. The ECS not only controls appetite, but specific appetites such as that of fat. The study identifies the places throughout the whole gut where this inhibitory signal occurs.
77. Storr MA, Bashashati M, Hirota C, et al. Differential effects of CB(1) neutral antagonists and inverse agonists on gastrointestinal motility in mice. Neurogastroenterol Motil. 2010;22(7): 787-96. e223.
78. Cavuoto P, McAinch AJ, Hatzinikolas G, et al. The expression of receptors for endocannabinoids in human and rodent skeletal muscle. Biochem Biophys Res Commun. 2007;364(1): 105-10.
79. Cavuoto P, McAinch AJ, Hatzinikolas G, et al. Effects of cannabinoid receptors on skeletal muscle oxidative pathways. Mol Cell Endocrinol. 2007;267(1-2): 63-9.
80. Esposito I, Proto MC, Gazzerro P, et al. The cannabinoid CB1 receptor antagonist rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating the expression of phosphatidylinositol-3-kinase. Mol Pharmacol. 2008;74(6): 1678-86.
81. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257(1): 79-83.
82. Juan-Pico P, Fuentes E, Bermudez-Silva FJ, et al. Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell. Cell Calcium. 2006;39(2): 155-62.
83. Bermudez-Silva FJ, Sanchez-Vera I, Suarez J, et al. Role of cannabinoid CB2 receptors in glucose homeostasis in rats. Eur J Pharmacol. 2007;565(1-3): 207-11.
84. Vilches-Flores A, Delgado-Buenrostro NL, Navarrete-Vazquez G, et al. CB1 cannabinoid receptor expression is regulated by glucose and feeding in rat pancreatic islets. Regul Pept. 2010;163(1-3): 81-7.
85. Getty-Kaushik L, Richard AM, Deeney JT, et al. The CB1 antagonist rimonabant decreases insulin hypersecretion in rat pancreatic islets. Obesity (Silver Spring). 2009;17(10): 1856-60.
86. • Benard G, Massa F, Puente N, et al. Mitochondrial CB(1) receptors regulate neuronal energy metabolism. Nat Neurosci. 2012;15(4): 558-64. This study reveals a novel mechanism for the metabolic actions of endocannabinoids. The presence of CB1 receptors in the membrane of a relevante percentage of neuronal mitochdria allows the ECS to control respiration and neurotransmission.
87. • Tedesco L, Valerio A, Dossena M, et al. Cannabinoid receptor stimulation impairs mitochondrial biogenesis in mouse white adipose tissue, muscle, and liver: the role of eNOS, p38 MAPK, and AMPK pathways. Diabetes. 2010;59(11): 2826-36. The activation of the ECS has a negative impact on mitochondrial development. This paper identifies the role of the ECS on mitochondriogenensis and explains the beneficial role of cannabinoid CB1 receptor antagonists on the number of active mitochondria.
88. Patti ME, Corvera S. The role of mitochondria in the pathogenesis of type 2 diabetes. Endocr Rev. 2010;31(3): 364-95.
89. Tedesco L, Valerio A, Cervino C, et al. Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes. Diabetes. 2008;57(8): 2028-36.
90. • Perwitz N, Wenzel J, Wagner I, et al. Cannabinoid type 1 receptor blockade induces transdifferentiation towards a brown fat phenotype in white adipocytes. Diabetes Obes Metab. 2010;12(2): 158-66. This paper sets the role for the peripheral CB1 receptor on brown to white adipocyte metaplasia. This mechanisms is sufficient to induce net weight loss.
91. van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005;365(9468): 1389-97.
92. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006;295(7): 761-75.
93. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353(20): 2121-34.
94. Pan C, Yoo HJ, Ho LT. Perspectives of CB1 Antagonist in Treatment of Obesity: Experience of RIO-Asia. J Obes. 2011;2011: 957268.
95. Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. 2006;368(9548): 1660-72.
96. Christensen R, Kristensen PK, Bartels EM, et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007;370(9600): 1706-13.
97. Christopoulou FD, Kiortsis DN. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity. J Clin Pharm Ther. 2011;36(1): 10-8.
98. Navarro M, Hernandez E, Munoz RM, et al. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport. 1997;8(2): 491-6.
99. Jagerovic N, Hernandez-Folgado L, Alkorta I, et al. Discovery of 5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-3-hexyl-1 h-1, 2, 4-triazole, a novel in vivo cannabinoid antagonist containing a 1, 2, 4-triazole motif. J Med Chem. 2004;47(11): 2939-42.
100. Chen RZ, Frassetto A, Lao JZ, et al. Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor. Eur J Pharmacol. 2008;584(2-3): 338-42.
101. Pavon FJ, Bilbao A, Hernandez-Folgado L, et al. Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-3-hexyl-1 H-1, 2, 4-triazole-LH 21. Neuropharmacology. 2006;51(2): 358-66.
102. Pavon FJ, Serrano A, Perez-Valero V, et al. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats. J Neuroendocrinol. 2008;20 Suppl 1: 116-23.
103. • Alonso M, Serrano A, Vida M, et al. Anti-obesity efficacy of LH-21, a cannabinoid CB(1) receptor antagonist with poor brain penetration, in diet-induced obese rats. Br J Pharmacol. 2012;165(7): 2274-91. This study describes the effects of a cannabinoid CB1 receptor antagonist with poor brain penetration on diet-induced obese rats, identiying the adipose tissue as main target for its antiobesity actvity.
104. Tam J, Vemuri VK, Liu J, et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest. 2010;120(8): 2953-66.
105. Randall PA, Vemuri VK, Segovia KN, et al. The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior. Pharmacol Biochem Behav. 2010;97(1): 179-84.
106. • Cluny NL, Vemuri VK, Chambers AP, et al. A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. Br J Pharmacol. 2010;161(3): 629-42. Another description of a molecule that blocks cannabinoid receptors but does not penetrate into the brain. This molecule reduces appetite and body weight gain without inducing malaise.
107. LoVerme J, Duranti A, Tontini A, et al. Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice. Bioorg Med Chem Lett. 2009;19(3): 639-43.
108. McElroy J, Sieracki K, Chorvat R. Non-brain-penetrant CB1 receptor antagonists as a novel treatment of obesity and related metabolic disorders. Obesity (Silver Spring). 2008;16(S47).
109. Son MH, Kim HD, Chae YN, et al. Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control. Int J Obes (Lond). 2010;34(3): 547-56.
110. Receveur JM, Murray A, Linget JM, et al. Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier. Bioorg Med Chem Lett. 2010;20(2): 453-7.
111. Greenway FL, Whitehouse MJ, Guttadauria M, et al. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring). 2009;17(1): 30-9.
112. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762): 656-60.
113. Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature. 2001;409(6817): 194-8.
114. Bodnar RJ. Endogenous opioids and feeding behavior: a 30-year historical perspective. Peptides. 2004;25(4): 697-725.
115. Verty AN, Singh ME, McGregor IS, et al. The cannabinoid receptor antagonist SR 141716 attenuates overfeeding induced by systemic or intracranial morphine. Psychopharmacology (Berl). 2003;168(3): 314-23.
116. Kirkham TC, Williams CM. Synergistic efects of opioid and cannabinoid antagonists on food intake. Psychopharmacology (Berl). 2001;153(2): 267-70.
117. Rowland NE, Mukherjee M, Robertson K. Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats. Psychopharmacology (Berl). 2001;159(1): 111-6.
118. Chen RZ, Huang RR, Shen CP, et al. Synergistic effects of cannabinoid inverse agonist AM251 and opioid antagonist nalmefene on food intake in mice. Brain Res. 2004;999(2): 227-30.
119. Thorpe AJ, Mullett MA, Wang C, et al. Peptides that regulate food intake: regional, metabolic, and circadian specificity of lateral hypothalamic orexin A feeding stimulation. Am J Physiol Regul Integr Comp Physiol. 2003;284(6): R1409-17.
120. Haynes AC, Jackson B, Overend P, et al. Effects of single and chronic intracerebroventricular administration of the orexins on feeding in the rat. Peptides. 1999;20(9): 1099-105.
121. Horvath TL, Diano S, van den Pol AN. Synaptic interaction between hypocretin (orexin) and neuropeptide Y cells in the rodent and primate hypothalamus: a novel circuit implicated in metabolic and endocrine regulations. J Neurosci. 1999;19(3): 1072-87.
122. Hervieu GJ, Cluderay JE, Harrison DC, et al. Gene expression and protein distribution of the orexin-1 receptor in the rat brain and spinal cord. Neuroscience. 2001;103(3): 777-97.
123. Crespo I, Gomez de Heras R, Rodriguez de Fonseca F, et al. Pretreatment with subeffective doses of Rimonabant attenuates orexigenic actions of orexin A-hypocretin 1. Neuropharmacology. 2008;54(1): 219-25.
124. Simansky KJ. Serotonergic control of the organization of feeding and satiety. Behav Brain Res. 1996;73(1-2): 37-42.
125. • Garfield AS, Heisler LK. Pharmacological targeting of the serotonergic system for the treatment of obesity. J Physiol. 2009;587(Pt 1): 49-60. A review on the role of serotonin in obesity and the effects of serotonergic drugs. Lorcaserin, a 5HT2C receptor agonist is the first drug approved for obesity after the case of the CB1 receptor antagonist Rimonabant.
126. Hermann H, Marsicano G, Lutz B. Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience. 2002;109(3): 451-60.
127. Jackson HC, Needham AM, Hutchins LJ, et al. Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat. Br J Pharmacol. 1997;121(8): 1758-62.
128. Casado A, Rodriguez VM, Portillo MP, et al. Sibutramine decreases body weight gain and increases energy expenditure in obese Zucker rats without changes in NPY and orexins. Nutr Neurosci. 2003;6(2): 103-11.
129. Luque CA, Rey JA. The discovery and status of sibutramine as an anti-obesity drug. Eur J Pharmacol. 2002;440(2-3): 119-28.
130. Ward SJ, Lefever TW, Jackson C, et al. Effects of a Cannabinoid1 receptor antagonist and Serotonin2C receptor agonist alone and in combination on motivation for palatable food: a dose-addition analysis study in mice. J Pharmacol Exp Ther. 2008;325(2): 567-76.
131. • Tallett AJ, Blundell JE, Rodgers RJ. Effects of acute low-dose combined treatment with rimonabant and sibutramine on appetite and weight gain in rats. Pharmacol Biochem Behav. 2010;97(1): 92-100. An example of combinatorial therapy in obesity: the combination of subeffective doses of a serotonin uptake inhibitor and a cannabinoid receptor antagonist.
132. Rodriguez De Fonseca F, Navarro M, Gomez R, et al. An anorexic lipid mediator regulated by feeding. Nature. 2001;414(6860): 209-12.
133. Serrano A, Del Arco I, Javier Pavon F, et al. The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats. Neuropharmacology. 2008;54(1): 226-34.
134. Zaitone SA, Essawy S. Addition of a low dose of rimonabant to orlistat therapy decreases weight gain and reduces adiposity in dietary obese rats. Clin Exp Pharmacol Physiol. 2012;39(6): 551-9.
135. • Verty AN, Lockie SH, Stefanidis A, et al. Anti-obesity effects of the combined administration of CB1 receptor antagonist rimonabant and melanin-concentrating hormone antagonist SNAP-94847 in diet-inudced obese mice. Int J Obes (Lond). 2012. Another example of a combinatorial therapy based on the association of a cannabinoid CB1 receptor antagonist and a melanin-concentrating hormone antagonist.
136. Costantino L, Barlocco D. Designed Multiple Ligands: Basic Research vs Clinical Outcomes. Curr Med Chem. 2012;19(20): 3353-87.
137. Alvarado M, Goya P, Macias-Gonzalez M, et al. Antiobesity designed multiple ligands: Synthesis of pyrazole fatty acid amides and evaluation as hypophagic agents. Bioorg Med Chem. 2008;16(23): 10098-105.
138. • Perez-Fernandez RF, N; Macias, M; Elguero, J, et al. Dicovery of potent dual PPAR alpha agonists / CB1 ligands. Med Chem Lett. 2011: 793-7. This paper demonstrates that it is possible to create new chemical entities based in known cannabinoid CB1 receptor ligands that act as dual drugs: in this case, the second target is the PPARα receptor.